The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70549 ↗At a glance
Journal article in CNS Neuroscience & Therapeutics, 2025. Written by Lizhi Li and 10 co-authors. Institution: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Major MEDLINE topics: Parkinson Disease, Disease Progression, Receptors, Cell Surface. Cited 1 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Technology Major Project of Hunan Provincial Science and Technology Department, National Key Research and Development Program of China, the National Key Plan for Scientific Research and Development of China.
Abstract (original language)
Aims
The study aimed to investigate the role of NUS1 variants in Parkinson's disease (PD) progression and evaluate plasma Nogo‐B receptor (NgBR) as a potential biomarker.
Methods
We recruited 228 PD patients, including 38 with NUS1 variants ( NUS1 ‐PD) and 190 without (GU‐PD), and all underwent at least two follow‐up visits. Linear mixed‐effects models assessed motor and non‐motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.
Results
NUS1 ‐PD demonstrated an earlier age at onset and more severe motor features than GU‐PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off‐medication) in NUS1 ‐PD and GU‐PD, but a slower progression rate of urinary function in NUS1 ‐PD ( p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III ( p = 0.006) and cognitive impairment ( p = 0.010).
Conclusion
NUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Centre for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, China.
- Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Centre for Medical Genetics, Central South University, Changsha, China.
ORCID profiles: Xuxiang Zhang, Qian Xu, Qiying Sun, Jinchen Li, Jifeng Guo
Funding
- the Technology Major Project of Hunan Provincial Science and Technology Department
- National Key Research and Development Program of China
- the National Key Plan for Scientific Research and Development of China
Cite
APA
Li, L., Huang, J., Xiang, Y., Zhang, X., Xu, Q., Sun, Q., Liu, Z., Yan, X., Li, J., Tang, B., & Guo, J. (2025). The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70549
Vancouver
Li L, Huang J, Xiang Y, Zhang X, Xu Q, Sun Q, et al. The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70549
BibTeX
@article{Li2025,
author = {Li, Lizhi and Huang, Juanjuan and Xiang, Yaqin and Zhang, Xuxiang and Xu, Qian and Sun, Qiying and Liu, Zhenhua and Yan, Xinxiang and Li, Jinchen and Tang, Beisha and Guo, Jifeng},
title = {The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70549}
}
EUVIMED